ArticleThe British journal of radiology2022
SPIO-enhanced 0.35T MRI-guided radiotherapy for liver malignancies: usefulness in tumor visualization.
Article in The British journal of radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 8 citations in OpenAlex.
- Prospective evaluation of liver cancer volumes on non-contrast 1.5 T MR Linac imaging.Clinical and translational radiation oncology · 2026Article
- Different conjugates of FeRSC advances · 2025Article
- Article
- Advancing MRI with magnetic nanoparticles: a comprehensive review of translational research and clinical trials.Nanoscale advances · 2024Review
- IONPs-Based Medical Imaging in Cancer Care: Moving Beyond Traditional Diagnosis and Therapeutic Assessment.International journal of nanomedicine · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe purpose of this study was to investigate the changes of tumor-to-liver signal ratio in a 0.35T MRI-guided radiotherapy system and to evaluate the usefulness and pitfalls of superparamagnetic iron oxide (SPIO) administration for visualization of liver tumors.
methodsForty-two patients treated with MRI-guided stereotactic ablative radiotherapy (SABR) for liver tumors were included in this study. The tumor-to-liver signal ratios before and after SPIO administration were retrospectively assessed and compared on true fast imaging with steady-state precession (FISP).
resultsBefore SPIO administration, liver tumors were either invisible or barely visible in 15 cases (36%), but all tumors became visible after SPIO administration. The mean values of tumor-to-liver signal ratio before and after SPIO administration were 0.939 ± 0.201 and 1.336 ± 0.300, respectively (mean ± standard deviation,
conclusionsThis study showed that liver tumors that are invisible on true FISP imaging can be made visible by administration of SPIO, and that MRI-guided SABR can be performed accurately. ADVANCES IN KNOWLEDGE: This is the first report to examine the usefulness of liver-specific contrast agent superparamagnetic iron oxides in 0.35T MRI-guided radiation therapy. Liver tumors that are invisible on true fast imaging with steady-state precession can be made visible by administration of superparamagnetic iron oxides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.